Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-02
2011-08-02
Anderson, James (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07989490
ABSTRACT:
Liquid formulations, including solutions and suspensions of the various drugs, agents and/or compounds, may be locally or regionally delivered for the treatment of vascular disease. In each of these instances, antioxidants are utilized to prolong product integrity.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3959078 (1976-05-01), Guire
patent: 4350160 (1982-09-01), Kolesov et al.
patent: 4366819 (1983-01-01), Kaster
patent: 4368736 (1983-01-01), Kaster
patent: 4624257 (1986-11-01), Berggren et al.
patent: 4722906 (1988-02-01), Guire
patent: 4733665 (1988-03-01), Palmaz
patent: 4739762 (1988-04-01), Palmaz
patent: 4776337 (1988-10-01), Palmaz
patent: 4814470 (1989-03-01), Colin et al.
patent: 4857653 (1989-08-01), Colin et al.
patent: 4917090 (1990-04-01), Berggren et al.
patent: 4917091 (1990-04-01), Berggren et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5200534 (1993-04-01), Rao
patent: 5202448 (1993-04-01), Carver et al.
patent: 5229172 (1993-07-01), Cahalan et al.
patent: 5229529 (1993-07-01), Ueno et al.
patent: 5234447 (1993-08-01), Kaster et al.
patent: 5248796 (1993-09-01), Chen et al.
patent: 5254580 (1993-10-01), Chen et al.
patent: 5272171 (1993-12-01), Ueda et al.
patent: 5274137 (1993-12-01), Nicolaou et al.
patent: 5278324 (1994-01-01), Kingston et al.
patent: 5279949 (1994-01-01), Nair
patent: 5283253 (1994-02-01), Holton et al.
patent: 5294637 (1994-03-01), Chen et al.
patent: 5300638 (1994-04-01), Farina et al.
patent: 5308641 (1994-05-01), Cahalan et al.
patent: 5350800 (1994-09-01), Verhoeven et al.
patent: 5350866 (1994-09-01), Holton et al.
patent: 5352805 (1994-10-01), Kingston et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5380751 (1995-01-01), Chen et al.
patent: 5395850 (1995-03-01), Roth
patent: 5411984 (1995-05-01), Kingston et al.
patent: 5412092 (1995-05-01), Rey et al.
patent: 5415938 (1995-05-01), Cahalan et al.
patent: 5422364 (1995-06-01), Nicolaou et al.
patent: 5440056 (1995-08-01), Klein et al.
patent: 5496846 (1996-03-01), Wilson et al.
patent: 5681846 (1997-10-01), Trissel
patent: 5837313 (1998-11-01), Ding et al.
patent: 5924997 (1999-07-01), Campbell
patent: 6063780 (2000-05-01), Dexter et al.
patent: 6099562 (2000-08-01), Ding et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6136846 (2000-10-01), Rubinfeld et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6245026 (2001-06-01), Campbell et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6319923 (2001-11-01), Dexter et al.
patent: 6319943 (2001-11-01), Joshi et al.
patent: 6333348 (2001-12-01), Vogel et al.
patent: 6414014 (2002-07-01), Canetta et al.
patent: 6425898 (2002-07-01), Wilson et al.
patent: 6451339 (2002-09-01), Patel et al.
patent: 6458373 (2002-10-01), Lambert et al.
patent: 6509370 (2003-01-01), Joshi-Hangal et al.
patent: 6515016 (2003-02-01), Hunter
patent: 6538020 (2003-03-01), Joshi-Hangal et al.
patent: 6667048 (2003-12-01), Lambert et al.
patent: 6753006 (2004-06-01), Desai et al.
patent: 6828346 (2004-12-01), Joshi-Hangal et al.
patent: 6919370 (2005-07-01), Chen
patent: 2003/0087954 (2003-05-01), Palepu et al.
patent: 2003/0105156 (2003-06-01), Palepu et al.
patent: 2003/0187062 (2003-10-01), Zenoni et al.
patent: 2003/0207936 (2003-11-01), Chen
patent: 2005/0272806 (2005-12-01), Falotico et al.
patent: 617018 (1994-09-01), None
patent: 0 590 267 (2002-05-01), None
patent: 93/10076 (1993-05-01), None
patent: 93/23555 (1993-11-01), None
patent: 93/24476 (1993-12-01), None
patent: 94/00156 (1994-01-01), None
patent: 94/07876 (1994-04-01), None
patent: 94/07880 (1994-04-01), None
patent: 94/07881 (1994-04-01), None
patent: 94/07882 (1994-04-01), None
patent: 94/20089 (1994-09-01), None
patent: 99/45918 (1999-09-01), None
patent: 00/71163 (2000-11-01), None
patent: 01/30319 (2001-05-01), None
patent: 02/43765 (2002-06-01), None
patent: 03/057208 (2003-07-01), None
patent: 2004/091506 (2004-10-01), None
Ajroldi, G. et al., “Fluoroelastomers-dependence of relaxation phenomena on composition,” Polymer, 1989, 30, 2180-2187.
Berk, B. C. et al., “Heparins and Glucocorticoids Inhibit Restenosis,” J. Am. Coll. Cardiol., 1991, 17, 111B-117B.
Beutler, E., “Cladribine (2-chlorodeoxyadenosine),” Lancet, Oct. 17, 1992, 340(8825), 952-956.
Brehm, B. R. et al., “Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells,” J Cardiovasc Pharmacol, Nov. 2000, 36(5 Suppl 1), S401-S403.
Brehm, B. R. et al., “Chronically elevated endothelin-1 concentrations modulate the beta-adrenergic receptor system in vitro and in vivo,” J Cardiovasc Pharmacol. Nov. 2000, 36(5 Suppl 1), S157-S159.
Campbell, G. R. and Campbell, J. H., “Phenotypic Modulation of Smooth Muscle Cells in Primary Culture,” In:Vascular Smooth Muscle in Culture, vol. 1, Ch. 4, Boca Raton, FL: CRC, 1987, pp. 39-55.
Campbell, G. R., et al., “Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis,” Exp. Mol. Pathol., Apr. 1985, 42(2), 139-162.
Carrera, C. J. et al., “Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy,” J. Clin. Invest, 1990 86(5), 1480-1488.
Carson, D. A. et al., “DNA strand breaks, NAD metabolism, and programmed cell death,” Exp Cell Res, Jun. 1986,164(2), 273-281.
Carson, D. A. et al., “Genetic analysis of deoxyadenosine toxicity in dividing human lymphoblasts,” Adv Exp Med Biol, 1986, 195 Pt B, 207-211.
Carson, D. A. et al., “Lymphocyte dysfunction after DNA damage by toxic oxygen species. A model of immunodefciency,” J Exp Med., Mar. 1, 1986; 163(3), 746-751.
Carson, D. A. et al., “Metabolism to methionine and growth stimulation by 5′-methylthioadenosine and 5′-methylthioinosine in mammalian cells,” Biochem Biophys Res Commun, Apr. 29, 1983, 112(2), 391-397.
Carson, D. A. et al., “Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes,” Blood, Oct. 1983, 62(4), 737-743.
Chang, M. W. et al., “Adenovirus-mediated Over-expression of the Cyclin/Cyclindependent,” J. Clin. Invest., 1995, 96, 2260-2268.
Clowes, A. W. et al., “Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration,” Circ. Res., 1986, 58(6), 839-845.
Clowes, A. W. et al., “Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin,” Lab. Invest., 1985, 52(6), 611-616.
Clowes, A. W. et al., “Significance of quiescent smooth muscle migration in the injured rat carotid artery,” Circ Res. 1985, 56(1), 139-145.
Clowes, A. W., “Suppression by heparin of smooth muscle cell proliferation in injured arteries,” Nature, 1977, 265(5595), 625-626.
Colburn, M. D. et al., “Dose responsive suppression of myointimal hyperplasia by dexamethasone,” J. Vasc. Surg., 1992, 15, 510-518.
Currier, J. W. et al., “Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit,” Circ., 1989, 80(4), 11-66 (Abstract No. 0263).
Deroanne, C. F. et al., “Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling,” Oncogene, 2002, 21 (3), 427-436.
Edelman, E. R. et al., “Pathobiologic responses to stenting,” Am J. Cardiol. 1998, 81(7A), 4E-6E.
Farb, A. et al., “Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein,” Circ. Res., 1997, 80, 542-550.
Ferns, G. A. A. et al., “Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF,” Science,
Falotico Robert
Zhao Jonathon Z.
Anderson James
Cordis Corporation
Evens Carl J.
LandOfFree
Injectable formulations of taxanes for cad treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Injectable formulations of taxanes for cad treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injectable formulations of taxanes for cad treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662235